Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415441 | 0.86 | FFAR1 (0.68) | FFAR1SRD5A2NR3C1FFAR4PTGDR2 | |
| SCHEMBL3602690 | 0.84 | SRD5A2 (0.58) | FFAR1SRD5A2NR3C1PPARDPARP10 | |
| Hydrochloric Acid SCHEMBL8694026 | 0.84 | FFAR1 (0.67) | FFAR1SRD5A2NR3C1FFAR4PTGDR2 | |
| SCHEMBL15096166 | 0.83 | LTA4H (0.49) | FFAR1FFAR4PARP10PARP3 | |
| Methane SCHEMBL27637860 | 0.83 | FFAR1 (0.65) | FFAR1SRD5A2NR3C1FFAR4PTGDR2 | |
| SCHEMBL1421946 | 0.82 | PPARG (0.61) | FFAR1SRD5A2NR3C1FFAR4PTGDR2 | |
| SCHEMBL7911502 | 0.81 | FFAR1 (0.59) | FFAR1SRD5A2NR3C1FFAR4 | |
| SCHEMBL7911513 | 0.79 | PLA2G4B (0.67) | FFAR1SRD5A2NR3C1FFAR4PLA2G4B | |
| SCHEMBL12577967 | 0.79 | RAB9A (0.62) | FFAR1FFAR4 | |
| SCHEMBL8969156 | 0.79 | SRD5A2 (0.70) | FFAR1SRD5A2NR3C1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | FFAR1 21/4885SRD5A2 208/4885NR3C1 1/4885 |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | FFAR1 21/4885SRD5A2 208/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.